Precision Biosciences, Inc.

Precision Biosciences, Inc. company information, Employees & Contact Information

Precision BioSciences, Inc. (Nasdaq: DTIL) is a clinical stage gene editing company developing in vivo gene editing with its highly precise and versatile ARCUS genome editing platform. ARCUS uses sequence-specific DNA-cutting enzymes, or nucleases designed for gene knock out, as well as highly complex edits for gene insertion and/or gene repair. Precision BioSciences is based in Durham, North Carolina. For more information about Precision BioSciences please visit www.precisionbiosciences.com.

Company Details

Employees
119
Founded
-
Address
302 East Pettigrew Street, Durham,north Carolina 27701,united States
Phone
(919) 314-5512
Email
pa****@****ces.com
Industry
Biotechnology Research
NAICS
Research and Development in Biotechnology (except Nanobiotechnology)
HQ
Durham, North Carolina
Looking for a particular Precision Biosciences, Inc. employee's phone or email?

Precision Biosciences, Inc. Questions

News

Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting - Business Wire

Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting Business Wire

Precision BioSciences Announces Publication in Nucleic Acids Research Elucidating the Mechanisms for High Efficiency Gene Insertion in Dividing and Non-Dividing Cells Using ARCUS Nucleases - Yahoo Finance

Precision BioSciences Announces Publication in Nucleic Acids Research Elucidating the Mechanisms for High Efficiency Gene Insertion in Dividing and Non-Dividing Cells Using ARCUS Nucleases Yahoo Finance

Precision BioSciences Announces Opening of First Clinical Trial Site in U.S. for ELIMINATE-B Trial - Business Wire

Precision BioSciences Announces Opening of First Clinical Trial Site in U.S. for ELIMINATE-B Trial Business Wire

Precision BioSciences to Report Second Quarter 2025 Results on August 7, 2025 - Yahoo Finance

Precision BioSciences to Report Second Quarter 2025 Results on August 7, 2025 Yahoo Finance

Precision BioSciences Highlights New Preclinical Data for PBGENE-DMD Further Supporting Advancement of Novel Gene Editing Approach for the Treatment of Duchenne Muscular Dystrophy Towards Clinic - Business Wire

Precision BioSciences Highlights New Preclinical Data for PBGENE-DMD Further Supporting Advancement of Novel Gene Editing Approach for the Treatment of Duchenne Muscular Dystrophy Towards Clinic Business Wire

ARCUS Gene Editor Shows Promise Against Hepatitis B - CRISPR Medicine News

ARCUS Gene Editor Shows Promise Against Hepatitis B CRISPR Medicine News

Lilly and Precision BioSciences Announce Genome Editing Research Collaboration and License Agreement - PR Newswire

Lilly and Precision BioSciences Announce Genome Editing Research Collaboration and License Agreement PR Newswire

Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update - Business Wire

Precision BioSciences Reports Second Quarter 2025 Financial Results and Provides Business Update Business Wire

Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update - Business Wire

Precision BioSciences Reports First Quarter 2025 Financial Results and Provides Business Update Business Wire

Precision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B - Business Wire

Precision BioSciences Announces Phase 1 Safety and Efficacy for Cohort 1, Lowest Dose Level in ELIMINATE-B, a First-In-Human Trial of PBGENE-HBV for Chronic Hepatitis B Business Wire

Precision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy - Business Wire

Precision BioSciences Receives FDA Rare Pediatric Disease Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy Business Wire

Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy - Business Wire

Precision BioSciences Receives FDA Orphan Drug Designation for PBGENE-DMD for the Treatment of Duchenne Muscular Dystrophy Business Wire

Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL) - Business Wire

Precision BioSciences Announces Presentation of Initial Safety Data from the Phase 1 ELIMINATE-B Trial Evaluating PBGENE-HBV at the 2025 European Association for the Study of the Liver Congress (EASL) Business Wire

Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency - Business Wire

Precision BioSciences Announces Complete Clinical Response in First Infant Dosed by Partner iECURE in Ongoing Phase 1/2 Clinical Trial in Ornithine Transcarbamylase (OTC) Deficiency Business Wire

Allogeneic CAR-T Azer-Cel Achieves Complete Responses in Some Patients With Diffuse Large B-Cell Lymphoma - CGTLive®

Allogeneic CAR-T Azer-Cel Achieves Complete Responses in Some Patients With Diffuse Large B-Cell Lymphoma CGTLive®

First-Ever Successful Gene Insertion: iECURE's ECUR-506 Achieves Complete Response in Rare Infant Disease - Stock Titan

First-Ever Successful Gene Insertion: iECURE's ECUR-506 Achieves Complete Response in Rare Infant Disease Stock Titan

Precision BioSciences Hires Matt Kane as CEO - citybiz

Precision BioSciences Hires Matt Kane as CEO citybiz

Precision BioSciences Appoints Michael Amoroso Chief Executive Officer - Business Wire

Precision BioSciences Appoints Michael Amoroso Chief Executive Officer Business Wire

Precision BioSciences to Report Third Quarter Results on November 7, 2023 - FinancialContent

Precision BioSciences to Report Third Quarter Results on November 7, 2023 FinancialContent

Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement - The AI Journal

Precision BioSciences Announces Common Stock Purchase by Members of Management for $300,000 in a Private Placement The AI Journal

Precision BioSciences Appoints Michael Amoroso as Chief Executive Officer - citybiz

Precision BioSciences Appoints Michael Amoroso as Chief Executive Officer citybiz

Precision BioSciences Appoints Sam Wadsworth, Ph.D. and Shari Lisa Piré, J.D. to Board of Directors - citybiz

Precision BioSciences Appoints Sam Wadsworth, Ph.D. and Shari Lisa Piré, J.D. to Board of Directors citybiz

Precision Biosciences Appoints Dora Alvarado as Senior Vice President of Human Resources - GlobeNewswire

Precision Biosciences Appoints Dora Alvarado as Senior Vice President of Human Resources GlobeNewswire

Leading Top 10 Companies in Genome Editing - P&S Intelligence

Leading Top 10 Companies in Genome Editing P&S Intelligence

About Us - FinancialContent

About Us FinancialContent

Four Smith Anderson Clients Win 2016 Triangle Business Journal Life Sciences Awards - Smith Anderson

Four Smith Anderson Clients Win 2016 Triangle Business Journal Life Sciences Awards Smith Anderson

Precision BioSciences (DTIL) Stock Price, News & Analysis - MarketBeat

Precision BioSciences (DTIL) Stock Price, News & Analysis MarketBeat

DTIL Stock Price and Chart — NASDAQ:DTIL - TradingView

DTIL Stock Price and Chart — NASDAQ:DTIL TradingView

Top Precision Biosciences, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant